Novartis (NOVN) remibrutinib delivered comprehensive disease control in a Phase 3 RMS trial

Newsquawk · 2026-10-23

Novartis (NOVN) remibrutinib delivered comprehensive disease control in a Phase 3 RMS trial. Phase 3 readouts in a well-established indication tend to follow a familiar sequence: top-line efficacy and safety language first, full data at a medical congress later, then the regulatory filing, with the equity reaction on day one driven by whether the headline meets, beats or merely matches the comparator bar. 'Comprehensive disease control' is sponsor phrasing; what historically separates durable re-ratings from faded pops is the detail against the active comparator and standard-of-care benchmarks, since relapse-rate and disability-progression endpoints in relapsing multiple sclerosis are well quantified and investors price against them quickly. Remibrutinib is a BTK inhibitor, a class where prior programs across multiple sponsors have drawn scrutiny on liver safety signals, so the tolerability tables matter as much as the efficacy headline when the full dataset arrives. The peer read-across runs to other BTK programs in neurology and to incumbents in the MS franchise, where share shifts have historically been gradual given long treatment durations and payer friction. The follow-ons that tend to move the story are the congress presentation, the filing timeline, and any regulatory commentary on the class's safety profile. As a single-arm-of-information top-line release, the signal is positive but incomplete until the dataset is public. 23 Oct, 15:24 Eni (ENI IM) expected to sign infrastructure contracts worth up to USD 1.8bln for a gas project in Cyprus in the coming days, according to the WSJ 23 Oct, 07:03 European Movers: L'Oreal (OR FP) +4.8%, Holcim (HOLN SW) +4.5%, Hexagon (HEXAB SS) +3.0%, Eni (ENI IM) +2.3%, Kering (KER FP) -11.0%, Volvo Car (VOLCARB SS) -3.3% 23 Oct, 06:08 Additional European Equity News - 23rd October 2026 23 Oct, 05:59 Newsquawk Daily European Equity Opening News - 23rd October 2026 22 Oct, 12:12 Nokia (NOKIA FH) says Q3 operating margin expanded 220bps Y/Y to 11.7%, with FY26 Group outlook tracking above the midpoint of guidance Yara (YAR NO) says higher gas costs more than outweighed higher selling prices, pressuring Q3 margins Y/Y 1 day ago Atlas Copco (ATCOA SS) Q3 2026 (SEK): Orders 52.3bln (exp. 50.6bln, prev. 40.52bln Y/Y), revenue 47.9bln (exp. 47.7bln), adj. EBIT 10.2bln (exp. 10.3bln) 1 day ago European Movers: Hermes (RMS FP) -8%, Nokia (NOKIA FH), -0.8%, Nestle (NESN SW) +0.4%, Roche (ROP SW) +0.5%, SAP (SAP GY) +1%, Barclays (BARC LN) +1.8%, UCB (UCB BB) +13% 1 day ago EUROPEAN OPEN: SAP GY rises after earnings report; NOKIA FH Q3 profit/revenue beat; ROP SW Q3 sales top expectations; QIA GY agrees EUR 10.8bln EQT takeover; NESN SW Q3 organic sales growth beats; RMS FP Q3 revenue rises; BARC LN Q3 pretax profit rises 1 day ago Nokia (NOKIA FH) CEO expects supply chain constraints to continue in 2027, relief may not begin until 2028 1 day ago Additional European Equity News - 22nd October 2026 1 day ago European Pre-Market Summary 22nd October 2026: European bourses set for a weak open; SAP, Nokia, Nestle report strong results, whilst Hermes disappoints 1 day ago Newsquawk Daily European Equity Opening News - 22nd October 2026 1 day ago Nokia (NOKIA FH) Q3 2026 (EUR): Sales 5.15bln (exp. 5.06bln), Adj. EPS 0.09; FY Outlook Adj. Op. Profit 2.1-2.6bln (exp. 2.36bln) 1 day ago [EARNINGS PREVIEW] Roche (ROP SW) to kickstart European healthcare earnings on the 22th October at 06:00 BST / 01:00 EDT 1 day ago [EARNINGS PREVIEW] SAP to report Q3 results on 21 October; focus on AI adoption and cloud metrics 1 day ago DoJ reportedly asks Federal Court to remand Iberdrola's (IBE SM) Avangrid New England wind project approval 2 days ago [MARKET UPDATE] Modest upside seen across European equities, particularly the DAX, as Nvidia (NVDA) CEO speaks in Germany 2 days ago Delivery Hero (DHER GY) does not receive approval from Taiwan for the sale of the Foodpanda business to A2G Holding 2 days ago

AI 시장 분석

Novartis announced positive Phase 3 multiple sclerosis disease-modifying results for remibrutinib, sending a positive signal to the biotech sector. Additionally, tech earnings were solid, with Nokia's Q3 operating margin expanding by 220 bps to 11.7% and beating annual guidance. On the other hand, Yara experienced margin pressure due to rising gas prices, and European stock markets showed differentiated trends based on individual corporate earnings.

상승 영향

Biotech — Novartis's remibrutinib demonstrated comprehensive disease-modifying effects in Phase 3 trials, raising expectations for new drug value.
Telecom — Nokia's Q3 operating margin expanded by 220 bps to 11.7% and beat annual guidance, improving profitability.

하락 영향

Chemicals — Yara suffered margin pressure in Q3 as rising gas prices offset selling price increases, worsening profitability.

DYAX 전담 분석

Novartis's new drug clinical success and Nokia's margin improvement are direct drivers supporting the stock prices of related pharmaceutical and telecom equipment companies. In particular, the safety profile of the BTK inhibitor class and upcoming conference presentation data are expected to act as key variables for further re-rating.

In the bullish scenario, acceleration of regulatory approval following the full data release will allow related pharma stocks to gain a premium, but in the bearish scenario, caution is required as volatility could expand if liver safety concerns or supply chain constraints persist.

AI가 생성한 분석으로 투자 자문이 아닙니다.

DYAX Investor Sentiment

Bullish (Long) 44% · Bearish (Short) 56%

393 participants

Related News

원문 보기 — Newsquawk